UCL Cancer Institute


Welcome to the UCL Cancer Institute 

The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing better, more effective therapies for cancers and improve outcomes for cancer patients. If you are thinking about postgraduate study with us, applications to our flagship MSc Cancer programme are now open for the academic year 2017/18, or view details of our new funded PhD studentship project examining T cell responses, supervised by Dr Sergio Quezada and Dr Javier Herrero.


New research leads the way in epigenomic studies

Research led by UCL and Queen Mary University of London (QMUL) scientists has identified epigenetic changes in three types of immune cell that could contribute to the development of type 1 diabetes. These changes were only found in patients with diabetes, opening the door to future biomarker development. The study, published today in Nature Communications, employed a unique experimental design that can now allow researchers to more confidently interpret results from epigenomic studies.

Published: Nov 29, 2016 6:45:50 PM

Powerful analysis tool for epigenomic studies developed

Research published this week in Cell Reports highlights a powerful new data analysis tool that could vastly improve the interpretation of data gathered from epigenomic studies. The scientific team, led by UCL, have developed the eFORGE tool, which offers a new way to identify cell types that underlie complex human disease. The tool can enable researchers to draw more meaningful results from studies on cancer and other diseases, potentially speeding up the process of drug development.

Published: Nov 17, 2016 4:58:31 PM

BLUEPRINT celebrates major manuscript release

European epigenomes research project, BLUEPRINT, today announced the release of a collection of 26 publications in Cell, Cell Press-associated and other high-impact journals. The papers are part of a package of 41 publications by the International Human Epigenome Consortium (IHEC) of which BLUEPRINT is a member. Many key papers within the release are authored by Professor Stephan Beck and his scientific team from the Medical Genomics group at UCL Cancer Institute.

Published: Nov 17, 2016 4:57:17 PM

Cancer Research UK-UCL Centre

Cancer Research UK-UCL Centre

The Cancer Research UK-UCL Centre is a network and partnership between Cancer Research UK, UCL and UCL's associated Hospital Trusts. The Centre's mission is to facilitate collaboration to advance world-class translational cancer research.

Study with us

Study with us

Our education programmes reflect the depth and breadth of research expertise within the UCL Cancer Institute. Join our community of research scientists and academic clinicians through our postgraduate taught MSc Cancer or PhD studies.

Clinical Trials

Clinical Trials

The Cancer Research UK and UCL Cancer Trials Centre is one of the largest cancer trials centres in the UK. The CTC conducts multi-centre national and international phase III trials, feasibility studies and early phase I and II studies.

Our Research

Our Research

UCL is a world leader in interdisciplinary research. The UCL Cancer Institute is uniquely placed to leverage this multidisciplinary approach to advance discoveries in basic, translational and clinical cancer research.


UCL Cancer Institute Seminar Series

Dr Simona Parrinello, MRC Clinical Sciences Centre, Imperial College London, presents: Cell-cell communication in the normal and malignant neurovascular niche

Starts: Dec 7, 2016 12:00:00 PM

Support our work

UCL philanthropy campaign research and destroy

Find out how you can help us to continue research that will lead to breakthroughs in cancer therapies and benefit the lives of cancer patients.

Taking action for equality

Athena Swan silver logo

Connect with us